Valuation: enGene Therapeutics Inc.

Market Cap 105M 93.34M 86.16M 78.18M 146M 9.93B 149M 1.04B 410M 5.19B 392M 384M 16.39B P/E 2026 *
-0.85x
P/E 2027 * -1.03x
Enterprise Value -79.98M -71.4M -65.91M -59.81M -112M -7.59B -114M -794M -314M -3.97B -300M -294M -12.54B EV / Sales 2026 *
-
EV / Sales 2027 * 5.38x
Free-Float
99.89%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: enGene Therapeutics Inc.

1 day+5.70%
Current month-16.50%
1 month-16.50%
3 months-11.64%
6 months-79.48%
Current year-81.51%
1 week 1.54
Extreme 1.54
1.72
1 month 1.54
Extreme 1.54
2.02
Current year 1.4
Extreme 1.4
12.25
1 year 1.4
Extreme 1.4
12.25
3 years 1.4
Extreme 1.4
47.17
5 years 1.4
Extreme 1.4
47.17
10 years 1.4
Extreme 1.4
47.17
Manager TitleAgeSince
Chief Executive Officer 63 2024-07-21
Director of Finance/CFO 48 2026-07-15
Chief Tech/Sci/R&D Officer 56 2026-06-14
Director TitleAgeSince
Director/Board Member 57 2023-08-07
Director/Board Member 66 2023-12-17
Director/Board Member 66 2024-05-14
Date Insider Type Main position Quantity % Market Cap. Importance
9/22/26 Buy

Chief Technology Officer

5,102 0.0076%
7/16/26 Other

Interim Chief Business Officer

75,000 0.1120%
7/16/26 Other

Chief Financial Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+5.70%0.00%-78.77%-84.14% 105M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.82%+2.88%+36.68%+133.38% 38.32B
Weighted average by Cap. +0.39%+2.73%+47.54%+158.51%

Financials

2026 *2027 *
Net sales - 5.6M 5M 4.61M 4.19M 7.84M 531M 7.96M 55.54M 21.97M 278M 21M 20.55M 878M
Net income -124M -111M -103M -93.09M -174M -11.82B -177M -1.24B -489M -6.19B -467M -457M -19.52B -113M -100M -92.71M -84.13M -158M -10.68B -160M -1.12B -442M -5.59B -422M -413M -17.64B
Net Debt -185M -165M -152M -138M -258M -17.52B -262M -1.83B -724M -9.17B -692M -678M -28.94B -74.46M -66.48M -61.37M -55.69M -104M -7.07B -106M -739M -292M -3.7B -279M -273M -11.68B
Projected Income Statement - Annual - enGene Therapeutics Inc.
Logo enGene Therapeutics Inc.
enGene Therapeutics Inc. is a clinical-stage biotechnology company mainstreaming non-viral genetic medicine through the delivery of therapeutics to mucosal tissues and other organs. The Company's lead program is detalimogene voraplasmid (also known as detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene at high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene is being developed using its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
Employees
-
Date Price Change Volume
26-10-23 US$1.560 -1.27% 730,199
26-10-22 US$1.580 -3.07% 554,578
26-10-21 US$1.630 -2.40% 1,108,892
26-10-20 US$1.670 +5.70% 1,119,792
26-10-19 US$1.580 -5.39% 783,845
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - enGene Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
1.560USD
Average target price
3.286USD
Spread / Average Target
+110.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - enGene Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. ENGN Stock